Anti-Sporozoite Monoclonal Antibody for Malaria Prevention: Secondary Efficacy Outcome of a Phase II Randomized Trial

Investigators reported the prespecified secondary efficacy endpoint that used a Plasmodium 18S rRNA quantitative reverse transcription–PCR assay that is ~2,000-fold more sensitive than thick blood smear.